Alpha Cognition (ACOG) doubles H1 2026 revenue as cash burn accelerates
Alpha Cognition Inc. (ACOG) reported significant revenue growth in Q2 2026 and H1 2026, driven by strong sales of its Alzheimer's drug ZUNVEYL, with Q2 revenue up 283% year-over-year and H1 revenue up 110%. Despite this, the company remains unprofitable with a net loss …